San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investor, who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), filed a lawsuit over alleged violations of Federal Securities Laws by Aldeyra Therapeutics, Inc.

Investors who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 29, 2023. NASDAQ: ALDX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Lexington, MA based Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.

In December 2022, Aldeyra Therapeutics, Inc. submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (the "ADX-2191 NDA").

On June 21, 2023, Aldeyra Therapeutics, Inc. issued a press release "announc[ing] receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL)." The press release stated that "[a]lthough no safety or manufacturing issues with ADX-2191 were identified, the FDA stated that there was a 'lack of substantial evidence of effectiveness' due to 'a lack of adequate and well-controlled investigations' in the literature-based NDA submission."

Shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) declined from $11.94 per share on June 09, 2023, to as low as $5.47 per share on June 21, 2023.

The plaintiff claims that between March 17, 2022 and June 20, 2023, the Defendants made false and/or misleading statements and/or failed to disclose that the ADX-2191 NDA did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness, that as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form, that accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.